FINWIRES · TerminalLIVE
FINWIRES

雪佛龙公司完成惠斯通天然气设施维修,恢复全面液化天然气生产

-- 雪佛龙公司(CVX)周四表示,在热带气旋袭击澳大利亚惠斯通天然气设施后,其已完成部分设备的维修工作,液化天然气生产现已全面恢复。 3月下旬,热带气旋纳雷尔袭击了该设施,导致生产中断。 雪佛龙澳大利亚公司运营和维护总监丹尼·伍德尔表示:“与气旋相关的强风损坏了数百台空冷式换热器(也称为翅片风扇),这使得维修工作成为一项艰巨的任务。” 伍德尔说:“气旋过后大约一周,我们就恢复了西澳大利亚州客户的国内天然气生产,液化天然气的生产也逐步恢复。” 据公司网站显示,惠斯通液化天然气工厂由两条生产线组成,总产能为每年890万吨。

Price: $187.05, Change: $+0.73, Percent Change: +0.39%

Related Articles

Asia

Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%

Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.

$ASX:ONE
Asia

Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low

Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.

$ASX:PAR
Asia

Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%

Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.

$SHA:600703